The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Texas MPN Workshop 2021 | Unmet needs for polycythemia vera treatment
Jerry Spivak, MD, Johns Hopkins University School of Medicine, Baltimore, MD, outlines the unmet needs for polycythemia vera by discussing the current diagnostic tools and their challenges, as well as issues faced by patients who develop post-polycythemia vera myelofibrosis, an aspect which existing JAK inhibitors and interferons fail to address. Prof. Spivak also comments on the impacts of using hydroxyurea as frontline therapy. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.
